Syros Pharmaceuticals, Inc. - SYRS Income before deduction of interest, taxes and amortization
Syros Pharmaceuticals (SYRS) is currently restructuring its development pipeline and aggressively conserving capital following a series of setbacks. The EBITDA reflects this process, where the indicator determines the magnitude of the metric. The company previously developed innovative methods for controlling gene transcription. Today, business success relies on its patent portfolio and tamibarotene trials for leukemia.
Summary analytical data breakdowns for Syros Pharmaceuticals, Inc. (SYRS)
- stock value and consensus price forecast:
- issuer market value details:
- book capitalization information:
- debt level and financial liquidity data:
Total Debt to Capital Syros Pharmaceuticals|SYRS - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital Syros Pharmaceuticals Inc.|SYRS - Company Debts|Debt to Book Value Syros Pharmaceuticals|SYRS - Company Long-Term Debts|Company Short-Term Debts Syros Pharmaceuticals|Quick Liquidity Indicator syros.com
- earnings and valuation multiples information:
SYRS - Net Profit|Expected Net Profit Syros Pharmaceuticals|SYRS - Price to Earnings Ratio|Forward P/E Multiple syros.com|SYRS - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio Syros Pharmaceuticals|SYRS - Operating profit EBITDA|Net earnings per share for the last four quarters Syros Pharmaceuticals|SYRS - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months syros.com|SYRS - Earnings growth in current year|Earnings growth forecast for next year Syros Pharmaceuticals
Analysis of all company metrics:SYRS - Syros Pharmaceuticals, Inc
The complexity of reproducing the biotechnological processes of Syros Pharmaceuticals (SYRS) and its patent shield make operational efficiency a key indicator of business viability. By analyzing the EBITDA history, an investor can see the net cash flow from operating activities without the influence of debt load, which allows for the separation of fundamental capitalization growth from market speculation and prevents overpaying for the asset.
Who Syros Pharmaceuticals competes with
Operating income before deduction of amortization Tempus (TEM)|QGEN: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization IONS (ionispharma.com)|Repligen (RGEN) - Profit before payment of interest, taxes and amortization|Profit before deduction of interest, taxes, depreciation and amortization RNA (Avidity Biosciences Inc)|CRSP (CRISPR Therapeutics Corp) - Operating profit EBITDA|WGS: Income before deduction of interest, taxes and amortization|Operating profit EBITDA RARE|Operating profit EBITDA beamtx.com (BEAM)|Profit before payment of interest, taxes and amortization Sarepta SRPT|Income before deduction of interest, taxes and amortization TWST|TXG - Profit before payment of interest, taxes and amortization|Intellia Corp (NTLA) - Operating profit before deduction of amortization|STOK: Operating profit EBITDA|biolifesolutions.com (BLFS) - Operating profit EBITDA|WVE (Wave Life Sciences Ltd.) - Operating profit EBITDA|Operating profit before deduction of amortization Maze Therapeutics, Inc. (MAZE)|Operating profit EBITDA SION|PRME - Profit before interest, taxes and amortization|Taysha Gene Therapies - Operating profit before deduction of amortization|Operating profit EBITDA uniqure.com QURE|MGTX: Operating profit before deduction of amortization|REGENXBIO Inc - Company profit before taxes, interest and amortization|SLDB: Operating profit EBITDA|OCGN - Operating income before deduction of amortization|PACB (Pacific Biosciences) - Operating profit EBITDA|Operating profit before deduction of amortization benitec.com (BNTC)|Operating profit EBITDA DSGN|Operating profit EBITDA Rocket Pharma (RCKT)|Profit before payment of interest, taxes and amortization 4D Molecular Therapeutics Inc FDMT|Lexeo Therapeutics Inc. - Profit before payment of interest, taxes and amortization|KRRO - Profit before payment of interest, taxes and amortization|Operating income before deduction of amortization editasmedicine.com EDIT|Silence Therapeutics plc (SLN) - Profit before payment of interest, taxes and amortization|PRQR - Operating income before deduction of amortization|Operating profit before deduction of amortization CDXS|Profit before interest, taxes and amortization Sangamo BioSciences SGMO|Profit before payment of interest, taxes and amortization Nautilus Biotechnology (NAUT)|MGX (metagenomi.co) - Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Precision BioSciences, Inc. DTIL|Operating income before deduction of amortization Generation Bio Co (GBIO)|Boundless Bio, Inc - Operating profit EBITDA|XCUR (Exicure, Inc.) - Operating profit before amortization|imunon.com (IMNN) - Profit before payment of interest, taxes and amortization|Operating profit before amortization PHIO|MBIO (Mustang Bio Inc) - Operating profit EBITDA|Operating profit EBITDA TransCode|Profit before payment of interest, taxes and amortization Bionano Genomics, Inc. (BNGO)|Operating income before deduction of amortization Applied DNA Corp|bluebird bio, Inc. - Operating profit before deduction of amortization|ImmunoPrecise Antibodies Ltd (IPA) - Profit before interest, taxes and amortization|OMGA - Profit before payment of interest, taxes and amortization|Income before deduction of interest, taxes and amortization OMIC (Singular Genomics Systems, Inc.)|Regulus Therapeutics Inc (RGLS) - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization Telesis Bio, Inc (TBIO)|Profit before payment of interest, taxes and amortization TRACON Pharmaceuticals|unitybiotechnology.com (UBX) - Operating income before deduction of amortization
